Expression and role of SIRT1 in hepatocellular carcinoma

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 503-510

  Choi, Ha Na ^a   Bae, Jun Sang ^a   Jamiyandorj, Urangoo ^a   Noh, Sang Jae ^a   Park, Ho Sung ^a   Jang, Kyu Yun ^a   Chung, Myoung Ja ^a   Kang, Myoung Jae ^a   Lee, Dong Geun ^a   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Hepatocellular carcinoma; Silent mating type information regulation 2 homolog 1

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN P53; SIRTUIN 1; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA INTERFERENCE; SEX DIFFERENCE; VIRUS INFECTION; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, SMALL INTERFERING; SIRTUIN 1; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958185807     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1301     Document Type: Article

References (40)

1. Imai S, Armstrong CM, Kaeberlein M and Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800, 2000.
2. Voelter-Mahlknecht S and Mahlknecht U: Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylase gene sirtuin 1. Int J Mol Med 17: 59-67, 2006.
3. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW and Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015, 2004.
4. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM and Sinclair DA: Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627-638, 2004.
5. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK, Park JW, Kwon KB and Park BH: Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 58: 344-351, 2009.
6. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2 alpha promotes cell survival under stress. Cell 107: 137-148, 2001.
7. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159, 2001.
8. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer, a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
9. Chen WY, Wang DH, Yen RC, Luo J, Gu W and Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448, 2005.
10. Lim CS: Human SIRT1: a potential biomarker for tumorigenesis? Cell Biol Int 31: 636-637, 2007.
11. Saunders LR and Verdin E: Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504, 2007.
12. Hida Y, Kubo Y, Murao K and Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 299: 103-106, 2007.
13. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N, Abate-Shen C, Farnham P and Reinberg D: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102: 1859-1864, 2005.
14. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618, 2007.
15. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 41: 366-371, 2009.
16. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kim HS, Shim H and Moon WS: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32: 1523-1531, 2008.
17. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
18. Befeler AS and Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-1619, 2002.
19. Kim DG, Park SY, Kim H, Chun YH, Moon WS and Park SH: A comprehensive karyotypic analysis on a newly established sarcomatoid hepatocellular carcinoma cell line SH-J1 by comparative genomic hybridization and chromosome painting. Cancer Genet Cytogenet 132: 120-124, 2002.
20. Zambetti GP and Levine AJ: A comparison of the biological activities of wild type and mutant p53. FASEB J 7: 855-865, 1993.
21. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, Wang XW, Ried T and Deng CX: Impaired DNA damage response, genomic instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323, 2008.
22. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS and Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15: 4453-4459, 2009.
23. Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD and Caldas C: Differentiatial expression of selected histone modifier genes in human solid cancers. BMC Genomics 7: 90, 2006.
24. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380, 2004.
25. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP and Sinclair DA: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3: e2020, 2008.
26. Yamakuchi M, Ferlito M and Lowenstein CJ: miR-3a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105: 13421-13426, 2008.
27. Lupberger J and Hildt E: Hepatitis B virus-induced oncogenesis. World J Gastroenterol 13: 74-81, 2007.
28. Qu J, Lin J, Zhang S, Zhu Z, Ni C, Zhang S, Gao H and Zhu M: HBV DNA can bind to P53 protein and influence p53 transactivation in hepatoma cells. Biochem Biophys Res Commun 386: 504-509, 2009.
29. Oyagbemi AA, Azeez OI and Saba AB: Hepatocellular carcinoma and the underlying mechanisms. Afr Health Sci 10: 93-98, 2010.
30. Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Bréchot C and Paterlini-Bréchot P: Large-scaled analysis of hepatitis B virus (HBV) DNA integration in HBV-related hepatocellular carcinomas. Gut 54: 1162-1168, 2005.
31. Allison SJ, Jiang M and Milner J: Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. Aging 1: 316-327, 2009.
32. Jiang M and Milner J: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21: 6041-6048, 2002.
33. Ninomiya T, Mihara K, Fushimi K, Hayashi Y, Hashimoto-Tamaoki T and Tamaoki T: Regulation of the alpha-fetoprotein gene by the isoforms of ATBF1 transcription factor in human hepatoma. Hepatology 35: 82-87, 2002.
34. Lee KC, Crowe AJ and Barton MC: p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 19: 1279-1288, 1999.
35. Ogden SK, Lee KC, Wernke-Dollries K, Stratton SA, Aronow B and Barton MC: p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J Biol Chem 276: 42057-42062, 2001.
36. Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y, Joh T, Nakabayashi H, Vaziri H, Harris CC and Riabowol K: ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 63: 5785-5792, 2003.
37. Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457-10463, 2005.
38. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y and Kaneki M: Sirt1 inhibitor, Sirtinol, induces senescence-life growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25: 176-185, 2006.
39. Jung-Hynes B, Nihal M, Zhong W and Ahmad N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 284: 3823-3832, 2009.
40. Jung-Hynes B and Ahmad N: Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 8: 1478-1483, 2009.